Small Pharma to participate in Jefferies Conference and CNS Summit.
Aims to assess the safety & tolerability of IM and IV administration of SPL028.
Brings total to twelve granted patents across the Company’s full portfolio.
Second quarter 2023 highlights including last patient dosed.
Small Pharma Completes Enrollment In Phase IIa DMT-Assisted Psychotherapy Clinical Trial In Patients With Major Depressive Disorder
Dosing for primary endpoint now complete.
The ASPP has been approved by the TSX Venture Exchange.
Small Pharma to participate in H.C. Wainwright and Jefferies conferences.
The TSX Venture Exchange has accepted Small Pharma's application.
Study will explore the interaction between SSRI antidepressants and SPL026.
Further Composition of Matter protection for SPL028.